EP 2.9.8 Resistance to Crushing of Tablets: Full Compliance GuideEP 2.9.8 Tablet Crushing Strength

The EP 2.9.8 tablet crushing strength test — formally European Pharmacopoeia 2.9.8 Resistance to Crushing of Tablets — is the mandatory compendial method in the European Union and 30+ Council of Europe signatory territories for measuring the force required to fracture a tablet by diametral compression. The chapter specifies n = 10 tablets, requires reporting in newtons as mean and standard deviation, and obligates traceable equipment calibration.

Any tablet released to a European, UK (MHRA post-Brexit), Swiss, or EEA market must be tested against EP 2.9.8 or an equivalent that has been justified to the regulator. Unlike USP <1217>, which is informational, EP 2.9.8 is a mandatory General Method — there is no informational loophole. This guide covers the full chapter content, equipment specifications, the test procedure in detail, and the decision framework for dual-compliance with USP <1217>.

EP 2.9.8 Overview: Scope, Applicability and Regulatory Context

The European Pharmacopoeia is published by the European Directorate for the Quality of Medicines & HealthCare (EDQM), under the Council of Europe. EP 2.9.8 is legally binding across EU and EEA member states, the United Kingdom, Switzerland, Turkey, and 30+ observer/signatory countries. The chapter applies to uncoated and coated tablets — round, oblong, caplet, biconvex, chewable, orodispersible, sublingual, and effervescent tablets — whenever mechanical strength is a specification attribute.

Unlike USP <1217> which is informational (above 1000), EP 2.9.8 is a mandatory General Method. An EU-market batch released without a compliant 2.9.8 record is a regulatory failure. The chapter is triggered whenever the product monograph references 2.9.8, when the MA dossier cites 2.9.8 in the specification, or when tablet hardness is cited as a release attribute in a CMC/quality module.

• EP 2.9.7 Friability of Uncoated Tablets — harmonized with USP <1216>; typically run alongside 2.9.8
• EP 2.9.1 Disintegration of Tablets and Capsules — harmonized with USP <701>
• EP 2.9.5 Uniformity of Mass of Single-Dose Preparations
• EP 2.9.40 Uniformity of Dosage Units — harmonized with USP <905>
• EU GMP Annex 11 — governs the computerized system producing and managing the data; overlaps substantially with 21 CFR Part 11

Key Technical Provisions of the Chapter

EP 2.9.8 is short and operationally clear. The chapter defines resistance to crushing as the force needed to cause a tablet to break by applying force perpendicular to the tablet's diameter, via two opposing flat jaws. The provisions with direct impact on instrument selection and SOP writing are:

• Apparatus — two flat, polished, parallel, non-deformable jaws; one fixed, one moving at a controlled rate; must measure maximum force at fracture
• Calibration — instrument must be calibrated against a known mass or force standard; EU regulators prefer ISO/IEC 17025 accredited calibration services
• Sample size — exactly 10 tablets; mandatory, not a recommendation
• Tablet orientation — for non-round tablets, the direction of force application relative to tablet shape must be stated in the report
• Expression of results — mean and standard deviation in newtons (N); individual values must be kept in the record even though only mean ± SD is the compendial report

Equipment Requirements Under EP 2.9.8: Jaws, Force Range & Calibration

EP 2.9.8 is more explicit than USP <1217> about jaw requirements. Translating the chapter's functional provisions into concrete instrument specifications for a pharmaceutical texture analyzer:

Step-by-Step EP 2.9.8 Test Procedure

The following is a compliance-ready procedure for EP 2.9.8. Adapt to your product monograph, lab QMS, and EU Annex 11 software configuration.

• Pre-use verification — confirm calibration is current (sticker and audit trail); confirm environmental conditions: 21 ± 2 °C, 45 ± 15% RH; verify no unresolved OOS events
• User authentication — log in under your own user ID (Annex 11 §12); confirm role permissions allow test execution
• Install flat parallel tablet jaws — hardened, polished, non-deformable; verify parallelism (feeler gauge within manufacturer specification)
• Load cell selection — 500 N for most EP monographs; confirm load-cell serial number matches the method (software interlock)
• Load EP 2.9.8 SOP-locked method — test speed 1.0 or 2.0 mm/s; trigger force 0.05 N; break detection 40% force drop; acquisition 500 Hz; units newtons; statistics mean ± SD; n = 10
• Sample preparation — equilibrate 10 tablets to lab conditions; visually inspect; reject chipped, cracked, or laminated tablets; record lot number and batch ID
• Load each tablet — orient oblong/caplet across minor axis; round biconvex with flat band parallel to jaws; scored tablets with score perpendicular to applied force; record orientation
• Execute and inspect — upper jaw descends; software captures peak force; confirm clean diametral fracture; flag laminar, multiple-peak, or crumble events
• Compute statistics — mean in N; standard deviation in N; minimum and maximum; orientation notes per tablet
• Operator e-signature — Annex 11 §14: printed name, date/time, meaning (e.g., 'Tested by')
• Independent review — QC supervisor reviews force-distance curves, statistics, and audit trail; applies e-signature 'Reviewed and approved'
• Disposition — pass or fail per product monograph limits; if fail, OOS investigation per EU GMP Chapter 6 and local SOP
• Archive — raw data, processed results, operator signatures, and audit trail retained per retention schedule

EP 2.9.8 vs. USP 1217: Key Differences and Dual-Compliance Strategy

The most common question from multi-region tablet manufacturers: can one method serve both the US and EU markets? Yes — with the right protocol design. A single SOP and single dataset can cover both markets by applying the stricter EP requirement on every parameter.

Dual-Compliance Protocol for Multi-Region Release

A single SOP and single dataset can satisfy both EP 2.9.8 and USP <1217> using these rules. The KHT TA-30 reporting module can export both formats from a single test run.

• Sample size = 10 — EP n = 10 is the binding constraint; satisfies any USP monograph with n = 6 or n = 10 requirement
• Report in both formats — keep individual values for USP; compute and report mean ± SD for EP; the KHT TA-30 reporting module outputs both simultaneously
• Jaws to the stricter specification — polished hardened-steel flat parallel jaws meeting EP's explicit material requirement automatically satisfies USP <1217>
• Speed fixed and documented — 1.0 or 2.0 mm/s; record the exact value in the method
• Data system to the stricter specification — configure software to satisfy both 21 CFR Part 11 (US) and EU Annex 11; the rules overlap almost perfectly
• Calibration — ISO/IEC 17025 accredited service, traceable to SI; acceptable to both FDA and EMA
• Method validation per ICH Q2(R2) — applicable to both FDA and EMA submissions